All In Biotech

Drug Trial Radar · NCT00515554

HD18 for Advanced Stages in Hodgkins Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,500

Actual

Start

May 2008

Primary completion

Jul 2019

Study completion Jul 2020

Sponsor

Lead sponsor
University of CologneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.

Conditions

  • Hodgkins Lymphoma

Interventions

  • RituximabDrug

    addition of Rituximab to BEACOPP escalated

  • BEACOPP escalatedDrug

    chemotherapy with BEACOPP escalated

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1st Dept. of Medicine, Cologne University Hospital

    Cologne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.